These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16363279)
21. [Raynaud's phenomenon, laser Doppler, isothermal chamber. Exploration of normal and pathologic subjects]. Boccalon H; Ginestet-Venerandi MC; Puel P J Mal Vasc; 1985; 10(1):11-6. PubMed ID: 3156940 [TBL] [Abstract][Full Text] [Related]
22. Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon. Bunker CB; Foreman JC; Dowd PM J Invest Dermatol; 1991 Mar; 96(3):314-7. PubMed ID: 2002251 [TBL] [Abstract][Full Text] [Related]
23. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases. Rychlik-Golema W; Mastej K; Adamiec R Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543 [TBL] [Abstract][Full Text] [Related]
24. Evidence for an abnormal peripherally mediated vascular response to temperature in Raynaud's phenomenon. Walmsley D; Goodfield MJ Br J Rheumatol; 1990 Jun; 29(3):181-4. PubMed ID: 2357499 [TBL] [Abstract][Full Text] [Related]
25. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512 [TBL] [Abstract][Full Text] [Related]
26. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions. Langevitz P; Buskila D; Lee P; Urowitz MB J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942 [TBL] [Abstract][Full Text] [Related]
27. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476 [TBL] [Abstract][Full Text] [Related]
28. Laser Doppler flowmeter and standardized thermal test in normals and Raynaud's phenomenon. Boccalon HJ; Marguery MC; Ginestet MC; Puel PF Int Angiol; 1987; 6(2):107-18. PubMed ID: 3323348 [TBL] [Abstract][Full Text] [Related]
29. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. Khan F; Belch JJ J Rheumatol; 1999 Nov; 26(11):2389-94. PubMed ID: 10555898 [TBL] [Abstract][Full Text] [Related]
30. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon. Whitmore SE; Wigley FM; Wise RA J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682 [TBL] [Abstract][Full Text] [Related]
31. [Objective judgement on effects of medicine in patients with Raynaud's phenomenon--measurement of cutaneous blood flow using laser Doppler flowmeter and platelet aggregation activity]. Shimizu H; Konohana A; Tajima S; Nishikawa T Nihon Hifuka Gakkai Zasshi; 1987 Jan; 97(1):35-8. PubMed ID: 2952821 [No Abstract] [Full Text] [Related]
32. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. Wollersheim H; Thien T; van 't Laar A J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. Edwards CM; Marshall JM; Pugh M Clin Sci (Lond); 1999 Jun; 96(6):577-88. PubMed ID: 10334963 [TBL] [Abstract][Full Text] [Related]
34. The relationship between subjective vasospastic complaints and finger blood flow measurements in Raynaud's phenomenon. Leesmans E; Bartelink ML; Wollersheim H; Thien T Neth J Med; 1993 Aug; 43(1-2):13-7. PubMed ID: 8232689 [TBL] [Abstract][Full Text] [Related]
35. [Secondary Raynaud's syndrome: skin blood flow decrease between the ischemic episodes and prolongation of the vasoconstriction during the respiratory maneuvers]. Ortiz-Nieva G; Estañol B; Téllez-Zenteno JF; García-Villa M; Corona-Marco V; Padilla-Rubio J; Cardiel-Ríos MH; García-Ramos G Arch Cardiol Mex; 2004; 74(3):181-91. PubMed ID: 15559870 [TBL] [Abstract][Full Text] [Related]
36. [Blood rheology in Raynaud's disease]. Larcan A; Schmidt C; Stoltz JF; Voisin P J Mal Vasc; 1984; 9(1):1-6. PubMed ID: 6707529 [TBL] [Abstract][Full Text] [Related]
37. Influence of local finger cooling on laser Doppler flux and nailfold capillary blood flow velocity in normal subjects and in patients with Raynaud's phenomenon. Lütolf O; Chen D; Zehnder T; Mahler F Microvasc Res; 1993 Nov; 46(3):374-82. PubMed ID: 8121320 [TBL] [Abstract][Full Text] [Related]
38. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon. Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851 [TBL] [Abstract][Full Text] [Related]
39. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Watson HR; Belcher G Ann Rheum Dis; 1991 Jun; 50(6):359-61. PubMed ID: 1711834 [TBL] [Abstract][Full Text] [Related]
40. Correlation of infrared thermography and skin perfusion in Raynaud patients and in healthy controls. Schlager O; Gschwandtner ME; Herberg K; Frohner T; Schillinger M; Koppensteiner R; Mlekusch W Microvasc Res; 2010 Jul; 80(1):54-7. PubMed ID: 20144625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]